Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

The Phenotypic Hit-to-Probe Challenge.

Created on 12 Nov 2026

Authors

Sven Herschel, Thomas Ullrich, Enrico Schmidt, Jean Quancard, Dennis Schade

Published in

Journal of medicinal chemistry. Volume 69. Issue 21. Pages 24996-25011. Nov 12, 2026.

Abstract

Phenotypic drug discovery (PDD) fuels the clinical pipelines with first-in-class therapeutic modalities. Success rates depend on the quality of the assay models and can be hampered by resource-intensive processes of target and mode-of-action deconvolution. A critical part of this practice is generating focused sets of phenotypic probes to accelerate in vivo validation and to support target/concept tractability and translatability, raising the question of which phenotypic hit analogues to synthesize as high-quality chemical probes for a given campaign. Here, we outline recommendations and discuss criteria tailored to the specific demands of phenotypic probes. With examples of successful PDD programs, some of which have yielded approved first-in-class drugs, we illustrate common design principles. These underscore that phenotypic probes benefit from (a) availability of matched pairs of active/inactive stereoisomers, (b) ligand topology-guided optimization, and (c) exit vectors for ADME- and target deconvolution-driven acceleration of early in vivo proof-of-concept and advancement towards clinical candidates.

PMID:
43018560
Bibliographic data and abstract were imported from PubMed on 12 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 9
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement